You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlendronic acid
Accession NumberDB00630  (APRD00561)
TypeSmall Molecule
GroupsApproved
DescriptionAlendronic acid (alendronate) is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Paget’s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Paget’s disease.
Structure
Thumb
Synonyms
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
4-amino-1-hydroxybutane-1,1-diphosphonic acid
ABDP
Acide Alendronique
Acido Alendronico
Acidum Alendronicum
Alendronate
External Identifiers
  • G 704650
  • GTH 4
  • L 670
  • L 670452
  • MK 217
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-alendronatetablet5 mgoralAccel Pharma IncNot applicableNot applicableCanada
Accel-alendronatetablet10 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-alendronatetablet70 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-alendronatetablet10 mgoralAccord Healthcare Inc2012-03-20Not applicableCanada
Ach-alendronatetablet5 mgoralAccord Healthcare Inc2012-03-20Not applicableCanada
Ach-alendronatetablet70 mgoralAccord Healthcare Inc2012-03-20Not applicableCanada
Act Alendronatetablet70 mgoralActavis Pharma Company2005-06-14Not applicableCanada
Act Alendronatetablet40 mgoralActavis Pharma Company2005-06-14Not applicableCanada
Alendronatetablet70 mgoralSivem Pharmaceuticals Ulc2008-03-13Not applicableCanada
Alendronatetablet70 mgoralSanis Health Inc2010-07-30Not applicableCanada
Alendronatetablet40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Alendronatetablet70 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Alendronatetablet70 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Alendronate-70tablet70 mgoralPro Doc Limitee2008-07-11Not applicableCanada
Auro-alendronatetablet10 mgoralAuro Pharma Inc2012-07-26Not applicableCanada
Auro-alendronatetablet70 mgoralAuro Pharma Inc2012-07-26Not applicableCanada
Binostotablet, effervescent70 mg/1oralMission Pharmacal Company2012-09-03Not applicableUs
Dom-alendronatetablet70 mgoralDominion Pharmacal2006-08-17Not applicableCanada
Dom-alendronate-FCtablet70 mgoralDominion PharmacalNot applicableNot applicableCanada
Fosamaxtablet5 mgoralMerck Canada Inc1997-10-212010-07-30Canada
Fosamaxtablet70 mg/1oralMerck Sharp & Dohme Corp.1995-09-29Not applicableUs
Fosamaxtablet70 mg/1oralPhysicians Total Care, Inc.2010-02-17Not applicableUs
Fosamaxsolution70 mgoralMerck Canada Inc2004-04-302013-07-15Canada
Fosamaxtablet35 mg/1oralPhysicians Total Care, Inc.2001-02-05Not applicableUs
Fosamaxtablet, coated10 mg/1oralPhysicians Total Care, Inc.1996-12-19Not applicableUs
Fosamaxtablet40 mgoralMerck Canada Inc1996-12-312013-07-15Canada
Fosamaxtablet70 mgoralMerck Canada Inc2002-02-14Not applicableCanada
Fosamaxtablet5 mg/1oralPhysicians Total Care, Inc.2000-11-20Not applicableUs
Fosamaxtablet10 mgoralMerck Canada Inc1996-12-312011-11-10Canada
Gen-alendronatetablet5 mgoralGenpharm Ulc2005-08-252009-08-05Canada
Jamp-alendronatetablet5 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-alendronatetablet10 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-alendronatetablet70 mgoralJamp Pharma Corporation2012-06-18Not applicableCanada
Mint-alendronatetablet70.0 mgoralMint Pharmaceuticals Inc2012-11-21Not applicableCanada
Mint-alendronatetablet10.0 mgoralMint Pharmaceuticals Inc2012-11-21Not applicableCanada
Mint-alendronatetablet5.0 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-alendronatetablet10 mgoralMylan Pharmaceuticals Ulc2005-08-25Not applicableCanada
Mylan-alendronatetablet70 mgoralMylan Pharmaceuticals Ulc2006-09-29Not applicableCanada
PHL-alendronatetablet70 mgoralPharmel Inc2006-08-17Not applicableCanada
PMS-alendronatetablet70 mgoralPharmascience Inc2005-11-14Not applicableCanada
PMS-alendronate-FCtablet70 mgoralPharmascience Inc2006-08-15Not applicableCanada
Q-alendronatetablet70 mgoralQd Pharmaceuticals Ulc2012-08-012015-08-21Canada
Ran-alendronatetablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-06-04Not applicableCanada
Ran-alendronatetablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-06-04Not applicableCanada
Ran-alendronatetablet70 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-06-04Not applicableCanada
Ratio Alendronatetablet70 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-02-082014-09-19Canada
Riva Alendronatetablet40 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva Alendronatetablet70 mgoralLaboratoire Riva Inc2005-09-12Not applicableCanada
Sandoz Alendronatetablet5 mgoralSandoz Canada Incorporated2007-01-112016-08-03Canada
Sandoz Alendronatetablet10 mgoralSandoz Canada Incorporated2007-01-11Not applicableCanada
Sandoz Alendronatetablet40 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Alendronatetablet70 mgoralSandoz Canada Incorporated2007-01-11Not applicableCanada
Teva-alendronatetablet10 mgoralTeva Canada Limited2003-05-12Not applicableCanada
Teva-alendronatetablet5 mgoralTeva Canada Limited2003-12-23Not applicableCanada
Teva-alendronatetablet70 mgoralTeva Canada Limited2005-05-31Not applicableCanada
Van-alendronatetablet10 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-alendronatetablet70 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-alendronatetablet5 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alendronatetablet35 mg/1oralVirtus Pharmaceuticals2015-09-30Not applicableUs
Alendronatetablet70 mg/1oralVirtus Pharmaceuticals2015-09-30Not applicableUs
Alendronate Sodiumtablet70 mg/1oralBlu Pharmaceuticals, LLC2013-02-05Not applicableUs
Alendronate Sodiumtablet70 mg/1oralREMEDYREPACK INC.2013-05-132016-04-05Us
Alendronate Sodiumtablet70 mg/1oralDispensing Solutions Inc.2009-03-03Not applicableUs
Alendronate Sodiumtablet35 mg/1oralMylan Pharmaceuticals Inc.2011-03-25Not applicableUs
Alendronate Sodiumtablet70 mg/1oralVirtus Pharmaceuticals2013-12-15Not applicableUs
Alendronate Sodiumtablet70 mg/1oralUnit Dose Services2014-12-15Not applicableUs
Alendronate Sodiumtablet70 mg/1oralActavis Pharma, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet5 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Alendronate Sodiumtablet5 mg/1oralApotex Corp.2008-08-04Not applicableUs
Alendronate Sodiumtablet5 mg/1oralTeva Pharmaceuticals USA Inc2008-02-06Not applicableUs
Alendronate Sodiumtablet5 mg/1oralSun Pharma Global Inc.2008-09-10Not applicableUs
Alendronate Sodiumtablet70 mg/1oralPhysicians Total Care, Inc.2008-02-07Not applicableUs
Alendronate Sodiumtablet5 mg/1oralAvera Mc Kennan Hospital2015-04-08Not applicableUs
Alendronate Sodiumtablet35 mg/1oralWatson Laboratories, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet10 mg/1oralAurobindo Pharma Limited2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralRebel Distributors Corp2008-08-04Not applicableUs
Alendronate Sodiumtablet10 mg/1oralMylan Institutional Inc.2008-09-01Not applicableUs
Alendronate Sodiumtablet70 mg/1oralProficient Rx LP2008-02-06Not applicableUs
Alendronate Sodiumtablet35 mg/1oralTeva Pharmaceuticals USA Inc2008-02-06Not applicableUs
Alendronate Sodiumtablet70 mg/1oralMylan Pharmaceuticals Inc.2011-03-25Not applicableUs
Alendronate Sodiumtablet70 mg/1oralDepartment Of State Health Services, Pharmacy Branch2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralAidarex Pharmaceuticals LLC2008-02-06Not applicableUs
Alendronate Sodiumtablet35 mg/1oralREMEDYREPACK INC.2013-10-07Not applicableUs
Alendronate Sodiumtablet70 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-21Not applicableUs
Alendronate Sodiumtablet10 mg/1oralTeva Pharmaceuticals USA Inc2008-02-06Not applicableUs
Alendronate Sodiumtablet35 mg/1oralAscend Laboratories, LLC2011-09-012015-12-29Us
Alendronate Sodiumtablet10 mg/1oralNorth Star Rx Llc2008-08-04Not applicableUs
Alendronate Sodiumtablet10 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Alendronate Sodiumtablet10 mg/1oralApotex Corp.2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralAurobindo Pharma Limited2008-08-04Not applicableUs
Alendronate Sodiumtablet10 mg/1oralSun Pharma Global Inc.2008-09-10Not applicableUs
Alendronate Sodiumtablet10 mg/1oralPhysicians Total Care, Inc.2008-02-11Not applicableUs
Alendronate Sodiumtablet40 mg/1oralWatson Laboratories, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralRebel Distributors Corp2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralMylan Institutional Inc.2008-09-01Not applicableUs
Alendronate Sodiumtablet70 mg/1oralProficient Rx LP2008-08-04Not applicableUs
Alendronate Sodiumtablet5 mg/1oralMylan Pharmaceuticals Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet5 mg/1oralWatson Laboratories, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralJubilant Cadista Pharmaceuticals Inc.2011-07-01Not applicableUs
Alendronate Sodiumtablet70 mg/1oralAidarex Pharmaceuticals LLC2008-02-06Not applicableUs
Alendronate Sodiumtablet70 mg/1oralREMEDYREPACK INC.2013-10-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralCipla USA Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet40 mg/1oralTeva Pharmaceuticals USA Inc2008-02-06Not applicableUs
Alendronate Sodiumtablet70 mg/1oralAscend Laboratories, LLC2011-09-012015-12-29Us
Alendronate Sodiumtablet35 mg/1oralNorth Star Rx Llc2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Alendronate Sodiumtablet35 mg/1oralApotex Corp.2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralAurobindo Pharma Limited2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralSun Pharma Global Inc.2008-09-10Not applicableUs
Alendronate Sodiumtablet35 mg/1oralGolden State Medical Supply, Inc.2014-04-03Not applicableUs
Alendronate Sodiumtablet70 mg/1oralWatson Laboratories, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralBlu Pharmaceuticals, LLC2013-02-05Not applicableUs
Alendronate Sodiumsolution70 mg/75mLoralTAGI Pharma, Inc.2013-05-06Not applicableUs
Alendronate Sodiumtablet70 mg/1oralMed Vantx, Inc.2008-02-06Not applicableUs
Alendronate Sodiumtablet10 mg/1oralMylan Pharmaceuticals Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralCipla USA Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet10 mg/1oralWatson Laboratories, Inc.2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralJubilant Cadista Pharmaceuticals Inc.2011-07-01Not applicableUs
Alendronate Sodiumtablet35 mg/1oralAidarex Pharmaceuticals LLC2008-02-06Not applicableUs
Alendronate Sodiumtablet35 mg/1oralPhysicians Total Care, Inc.2008-02-07Not applicableUs
Alendronate Sodiumtablet70 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Alendronate Sodiumtablet70 mg/1oralApotex Corp.2008-08-04Not applicableUs
Alendronate Sodiumtablet70 mg/1oralTeva Pharmaceuticals USA Inc2008-02-06Not applicableUs
Alendronate Sodiumtablet70 mg/1oralAmerican Health Packaging2009-11-042015-12-29Us
Alendronate Sodiumtablet70 mg/1oralNorth Star Rx Llc2008-08-04Not applicableUs
Alendronate Sodiumtablet35 mg/1oralUnit Dose Services2014-12-15Not applicableUs
Alendronate Sodiumtablet70 mg/1oralSun Pharma Global Inc.2008-09-10Not applicableUs
Alendronate Sodiumtablet70 mg/1oralGolden State Medical Supply, Inc.2014-04-03Not applicableUs
Alendronate Sodiumtablet35 mg/1oralVirtus Pharmaceuticals2013-12-15Not applicableUs
Alendronate Sodiumtablet35 mg/1oralActavis Pharma, Inc.2009-10-23Not applicableUs
Apo-alendronatetablet40 mgoralApotex IncNot applicableNot applicableCanada
Apo-alendronatetablet5 mgoralApotex Inc2004-05-10Not applicableCanada
Apo-alendronatetablet10 mgoralApotex Inc2004-05-10Not applicableCanada
Apo-alendronatetablet70 mgoralApotex Inc2005-05-27Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlenotopPliva
AlnedLaboratorios Belmac
ArendalIvax
BeenosGedeon Richter
BerlexDuncan
DenfosBiofarma
DensidronMepha
DronatFarmavita
DurostPerumed
FixopanGrupo Farma
ForosaKemofarmacija
FosagenAspen Pharmacare
FosalenTeriak
FosminHospimedikka
FostolinActavis
FosvalSaval
HuesoboneFarmaceutica Latina
LendrateActavis
OseolenIntipharma
OstemaxPolpharma
Brand mixtures
NameLabellerIngredients
Alendronate-cholecalciferolFrosst A Division Of Merck Canada Inc
Apo-alendronate/vitamin D3Apotex Inc
Fosamax Plus DMerck Sharp & Dohme Corp.
FosavanceMerck Canada Inc
Sandoz Alendronate/cholecalciferolSandoz Canada Incorporated
Teva-alendronate/cholecalciferolTeva Canada Limited
Salts
Name/CASStructureProperties
Alendronate calcium
137504-90-6
Thumb
  • InChI Key: VFAZUESUCBECNE-UHFFFAOYSA-L
  • Monoisotopic Mass: 535.9803924
  • Average Mass: 536.253
DBSALT001780
Alendronate sodium
121268-17-5
Thumb
  • InChI Key: DCSBSVSZJRSITC-UHFFFAOYNA-M
  • Monoisotopic Mass: 325.0303635
  • Average Mass: 325.1237
DBSALT000315
Alendronate sodium anhydrous
129318-43-0
Thumb
  • InChI Key: CAKRAHQRJGUPIG-UHFFFAOYSA-M
  • Monoisotopic Mass: 270.99867001
  • Average Mass: 271.077
DBSALT001779
Categories
UNIIX1J18R4W8P
CAS number66376-36-1
WeightAverage: 249.096
Monoisotopic: 249.016724799
Chemical FormulaC4H13NO7P2
InChI KeyInChIKey=OGSPWJRAVKPPFI-UHFFFAOYSA-N
InChI
InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
IUPAC Name
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
SMILES
NCCCC(O)(P(O)(O)=O)P(O)(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Organophosphonic acid
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
PharmacodynamicsAlendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.
Mechanism of actionThe action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Related Articles
AbsorptionRelative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.
Volume of distribution
  • 28 L
Protein binding78%
Metabolism

There is no evidence that alendronate is metabolized in humans or animals.

Route of eliminationFollowing a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces.
Half life>10 years
Clearance
  • <200 mL/min [A single 10 mg IV dose]
ToxicityAlendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Alendronate Action PathwayDrug actionSMP00095
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9554
Blood Brain Barrier+0.7065
Caco-2 permeable-0.7079
P-glycoprotein substrateNon-substrate0.6606
P-glycoprotein inhibitor INon-inhibitor0.947
P-glycoprotein inhibitor IINon-inhibitor0.9894
Renal organic cation transporterNon-inhibitor0.9205
CYP450 2C9 substrateNon-substrate0.8536
CYP450 2D6 substrateNon-substrate0.7997
CYP450 3A4 substrateNon-substrate0.6792
CYP450 1A2 substrateNon-inhibitor0.7567
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorNon-inhibitor0.9344
CYP450 2C19 inhibitorNon-inhibitor0.9091
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9914
Ames testNon AMES toxic0.7079
CarcinogenicityNon-carcinogens0.7783
BiodegradationReady biodegradable0.6547
Rat acute toxicity1.6956 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8571
hERG inhibition (predictor II)Non-inhibitor0.8929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Austarpharma llc
  • Barr laboratories inc
  • Cadista pharmaceuticals inc
  • Dr reddys laboratories ltd
  • Genpharm ulc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharma global inc
  • Teva pharmaceuticals usa
  • Watson laboratories
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Solutionoral70 mg/75mL
Tabletoral10 mg/1
Tabletoral35 mg/1
Tabletoral40 mg/1
Tabletoral5 mg/1
Tablet, effervescentoral70 mg/1
Solutionoral70 mg
Tabletoral40 mg
Tabletoral70 mg/1
Tabletoral70 mg
Tablet, coatedoral10 mg/1
Tabletoral
Tabletoral10.0 mg
Tabletoral5.0 mg
Tabletoral70.0 mg
Tabletoral10 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Fosamax Plus D 4 70-2800 mg-Unit tablet Disp Pack107.66USD disp
Fosamax Plus D 4 70-5600 mg-Unit tablet Disp Pack107.66USD disp
Fosamax 1 Package = 4 tablet (70 mg) Package101.96USD package
Fosamax 1 Package = 4 tablet (35 mg) Package97.2USD package
Alendronate Sodium 4 35 mg tablet Package85.23USD package
Alendronate Sodium 4 70 mg tablet Package85.23USD package
Fosamax 70 mg/75ml Solution 75ml Bottle34.75USD bottle
Fosamax plus d 70 mg-5600 iu25.88USD each
Fosamax 70 mg tablet24.51USD tablet
Fosamax 35 mg tablet23.36USD tablet
Fosamax plus d 70 mg-2800 iu21.85USD each
Alendronate sodium 35 mg tablet20.49USD tablet
Alendronate sodium 70 mg tablet20.49USD tablet
Fosamax 40 mg tablet7.52USD tablet
Alendronate sodium 40 mg tablet6.73USD tablet
Fosamax 5 mg tablet3.4USD tablet
Fosamax 10 mg tablet3.4USD tablet
Alendronate sodium 10 mg tablet2.99USD tablet
Alendronate sodium 5 mg tablet2.99USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2190148 No2006-02-142015-05-12Canada
CA2294595 No2001-08-212018-07-17Canada
US5358941 No1992-12-022012-12-02Us
US5994329 Yes1999-01-172019-01-17Us
US6015801 Yes1999-01-172019-01-17Us
US6225294 Yes1999-01-172019-01-17Us
US7488496 No2003-08-112023-08-11Us
US7964212 No2003-03-062023-03-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point234 dec °CPhysProp
water solubility1mg/LNot Available
logP-4.3Not Available
pKa2.72 (at 25 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility16.9 mg/mLALOGPS
logP-1.3ALOGPS
logP-4.2ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.69ChemAxon
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity47.37 m3·mol-1ChemAxon
Polarizability19.4 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014i-2930000000-99692afb4ed253251947View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-001i-0900000000-d2c07307d66e1c7d52e8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0kdl-9500000000-c82a6e6e898154627c7dView in MoNA
References
Synthesis Reference

Masahiko Dohi, Yuji Makino, Takao Hujii, “Sodium alendronate preparation for local administration.” U.S. Patent US5958908, issued September, 1997.

US5958908
General References
  1. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [PubMed:18214569 ]
External Links
ATC CodesM05BA04M05BB03M05BB05M05BB06
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (105 KB)
MSDSDownload (24.7 KB)
Interactions
Drug Interactions
Drug
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alendronic acid.
Aluminum hydroxideThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum phosphate.
AmikacinAmikacin may increase the hypocalcemic activities of Alendronic acid.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Alendronic acid.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alendronic acid.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid.
Bismuth SubcitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Bismuth Subcitrate.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alendronic acid.
Calcium carbonateThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium carbonate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alendronic acid.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alendronic acid.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Alendronic acid.
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Alendronic acid.
DeferasiroxThe risk or severity of adverse effects can be increased when Alendronic acid is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Alendronic acid.
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Alendronic acid.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid.
EpirubicinEpirubicin may increase the hypocalcemic activities of Alendronic acid.
EsomeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Alendronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Alendronic acid.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Alendronic acid.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.
Ferric CitrateThe serum concentration of Alendronic acid can be decreased when it is combined with Ferric Citrate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Alendronic acid.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.
FramycetinFramycetin may increase the hypocalcemic activities of Alendronic acid.
GentamicinGentamicin may increase the hypocalcemic activities of Alendronic acid.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Alendronic acid.
Hygromycin BHygromycin B may increase the hypocalcemic activities of Alendronic acid.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Alendronic acid.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.
IdarubicinIdarubicin may increase the hypocalcemic activities of Alendronic acid.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid.
KanamycinKanamycin may increase the hypocalcemic activities of Alendronic acid.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.
LansoprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Alendronic acid.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid.
Magnesium carbonateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alendronic acid.
Magnesium SulfateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Sulfate.
Magnesium TrisilicateThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Trisilicate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alendronic acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.
MetrizamideMetrizamide may increase the hypocalcemic activities of Alendronic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alendronic acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Alendronic acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Alendronic acid.
NeomycinNeomycin may increase the hypocalcemic activities of Alendronic acid.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alendronic acid.
NetilmicinNetilmicin may increase the hypocalcemic activities of Alendronic acid.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alendronic acid.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.
OmeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Alendronic acid.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.
PantoprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.
ParomomycinParomomycin may increase the hypocalcemic activities of Alendronic acid.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alendronic acid.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alendronic acid.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.
PlicamycinPlicamycin may increase the hypocalcemic activities of Alendronic acid.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Alendronic acid.
PuromycinPuromycin may increase the hypocalcemic activities of Alendronic acid.
RabeprazoleThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.
RibostamycinRibostamycin may increase the hypocalcemic activities of Alendronic acid.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alendronic acid.
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Alendronic acid.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Alendronic acid.
StreptomycinStreptomycin may increase the hypocalcemic activities of Alendronic acid.
StreptozocinStreptozocin may increase the hypocalcemic activities of Alendronic acid.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Alendronic acid.
TAK-390MRThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with TAK-390MR.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Alendronic acid.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alendronic acid.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.
TobramycinTobramycin may increase the hypocalcemic activities of Alendronic acid.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alendronic acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Alendronic acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Alendronic acid.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Alendronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.
Food Interactions
  • Take 30-60 minutes before breakfast.
  • Take with a full glass of water.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Poly(a) rna binding
Specific Function:
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, d...
Gene Name:
FDPS
Uniprot ID:
P14324
Molecular Weight:
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603 ]
  4. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29. [PubMed:17535895 ]
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Non-membrane spanning protein tyrosine phosphatase activity
Specific Function:
May act at junctions between the membrane and the cytoskeleton.
Gene Name:
PTPN4
Uniprot ID:
P29074
Molecular Weight:
105910.315 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function:
Interacts with LAR-interacting protein LIP.1.
Gene Name:
PTPRS
Uniprot ID:
Q13332
Molecular Weight:
217039.825 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349 ]
  2. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function:
Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function (By similarity).Isoform 2 acts as a negative regulator of insulin receptor (IR) signaling in skeletal muscle. Regulates insulin-induced tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate 1 (I...
Gene Name:
PTPRE
Uniprot ID:
P23469
Molecular Weight:
80641.165 Da
References
  1. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-transporting atpase activity, rotational mechanism
Specific Function:
Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.
Gene Name:
ATP6V1A
Uniprot ID:
P38606
Molecular Weight:
68303.5 Da
References
  1. David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507. [PubMed:8889850 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28